Therapeutisches Drug Monitoring
| Title | Summary | Year |
| Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem | Suboptimal attainment of meropenem PK/PD targets may be a major determinant impacting on microbiological failure in critical COVID-19 patients with Gram-negative superinfections. Measured with MassTox TDM Series A. | 2022 |
| The Effect of Pregabalin on the Minimum Alveolar Concentration of Sevoflurane: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial | According to the study, pregabalin use led to a small reduction in post-operative pain levels but increased side effects in a dose-dependent manner. The drug was mesaured with MassTox Series A. | 2022 |
| Impaired Pharmacokinetics of Amiodarone under Veno-Venous Extracorporeal Membrane Oxygenation: From Bench to Bedside | Higher doses of amiodarone should be considered for effective amiodarone exposure under veno-venous extracorporeal membrane oxygenation (VV ECMO). Amiodarone measured with MassTox Series A. | 2022 |
| Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization | findings suggest that Css/MIC ratio ≥4.63 may be considered the pharmacodynamic target useful at maximizing the efficacy of CI meropenem in the treatment of Gram-negative infections in critically ill patients. Meropenem measured with Chromsystems assay. | 2021 |
| High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19 | Due to the high EC50 of SARS-CoV-2 and the fact that LPV/RTV is highly protein bound, it seems unlikely that LPV/RTV exhibits a relevant antiviral effect against SARS-CoV-2 in vivo. MassTox Series A was used for the determination of the drugs. | 2021 |
| Comparing posaconazole and itraconazole for antifungal prophylaxis in critically ill lung transplant recipients: efficacy and plasma concentrations | The findings suggest that posaconazole should be used instead of itraconazole for systemic prophylaxis in critically ill lung transplant recipients. Both analytes were determined with MassTox Series A | 2021 |
| Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole | The majority of patients achieved s-isavuconazole levels well within the therapeutic range with less intra/interindividual CV than patients receiving voriconazole. Drug concentrations were measured with an HPLC assay from Chromsystems. | 2021 |
| Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum | The paper describes a multi-analyte LC-MS/MS method for the quantification of repurposed COVID-19 drugs in human serum. It uses the column of Series A in combination with calibrators and controls for the COVID-19 drugs from Chromsystems. | 2021 |
| Drug–drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment | Concomitant administration of itraconazole capsule with efavirenz significantly reduced itraconazole and hydroxyitraconazole exposures. The clinical impact of this drug–drug interaction on talaromycosis treatment or prophylaxis in the era of potent ART needs further evaluation. Itraconazole and hydroxyitraconazole were measured with MassTox Series A | 2021 |
| Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study | ECMO treatment was associated with significantly reduced serum concentrations of specific antibiotics. Future studies are needed to assess the pharmacokinetic characteristics of antibiotics in ICU patients on ECMO support. Antbiotics were measured with the Chromsystems HPLC assay. | 2020 |
| Application Note: Therapeutic Drug Monitoring of COVID-19 Drugs with Components of a Commercial Assay | This protocol shows that MassTox® TDM Series A can be employed for the determination of 9 COVID-19 drug candidates/metabolites in serum/plasma. Laboratories that have already MassTox® TDM Series A in operation can simply use the same chromatographic set up, sample prep and MasterColumn® A. | 2020 |
| Aneurysmal Subarachnoid Hemorrhage: Impact on Phenytoin Permeability across the Blood–Brain Barrier | There is a definite decrease in the penetration of phenytoin to the brain in patients with grade 3 and 4 following aneurysmal subarachnoid hemorrhage. Phenytoin was measured with MassTox Series A | 2020 |
| Distribution of Psychotropic Drugs Into Lipoproteins | The present results indicate that psychotropic drugs with certain characteristics bind to LDL/VLDL in blood. This further implies that lipoproteins could play an important role in drug transport. Drugs were measured with MassTox Series A Calibrator Sets |
2019 |
| Short communication: Distribution of psychotropic drugs into lipoproteins | The present results indicate that psychotropic drugs with certain characteristics bind to LDL/VLDL in blood. This further implies that lipoproteins could play an important role in drug transport.. Measured with MassTox TDM Series A | 2019 |
| Interindividual and Intraindividual Variation of Methylphenidate Concentrations in Serum and Saliva of Patients With Attention-Deficit/Hyperactivity Disorder | Data indicate that the interindividual variation in saliva to serum concentrations is rather high, whereas the intraindividual variation is fairly low. Methylphenidate and ritalinic acid were measured with MassTox TDM Series A. | 2018 |
| Serum and Saliva Concentrations of Venlafaxine, O-Desmethylvenlafaxine, Quetiapine, and Citalopram in Psychiatric Patients | Saliva therapeutic drug monitoring of psychoactive drugs might become a useful approach to achieving individual treatment regimens. Drugs were measured with MassTox TDM Series A. | 2018 |
| The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy | Monitoring LEV Cmax values may enhance LEV adherence because patients would be less likely to develop adverse effects. LEV was measured with MassTox TDM Series A. | 2018 |
| Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient Variability | Considering the percentage of therapeutic azole plasma trough levels and the intrapatient variability, posaconazole tablets seem to be the most reliable choice of antimycotic therapy in lung transplant recipients. MassTox TDM Series A was used with antimycotics parameter set. | 2017 |
| Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians. | The HPLC assay from Chromsystems has been used in clinical research | 2015 |
| Effects of Antiepileptic Drug Monotherapy on One-Carbon Metabolism and DNA Methylation in Patients With Epilepsy | The findings suggest that the effects of AED monotherapy on one-carbon metabolism may induce specific regions of DNA hypomethylation. Valproate and lamotrigine was measured by HPLC | 2015 |
| Effects of Antiepileptic Drug Monotherapy on One-Carbon metabolism and DNA Methylation in Patients with Epilepsy | The findings suggest that the effects of AED monotherapy on one-carbon metabolism may induce specific regions of DNA hypomethylation. Chromsystems HPLC was used for the determination of valproic acid and lamotrigine. | 2015 |
| Carbamazepine Clearance and Seizure Stability During Pregnancy | Carbamazepine monotherapy may be a relatively safe and cost effective treatment option for women with focal epilepsy syndromes during pregnancy. Carbamazepine and ist epoxide was measured by the Chromsystems HPLC assay | 2014 |
| Carbamazepine clearance and seizure stability during pregnancy. | Chromsystems HPLC used in clinical research | 2014 |
| Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison With Healthy Volunteers | In morbidly obese patients, systemic clearance of midazolam is unchanged, while oral bioavailability is increased. The MassTox Series A assay was used for midazolam | 2014 |
| MODEL-BASED LAMOTRIGINE CLEARANCE CHANGES DURING PREGNANCY: CLINICAL IMPLICATION | An increase in changes in the oral clearence of lamotrigine may correspond to decreases in lamotrigine blood concentrations necessitating the need for more frequent dosage adjustments and closer monitoring in some pregnant women with epilepsy. Lamotrigine was measured by HPLC with an Chromsystems assay. | 2014 |
| THERAPEUTIC DRUG MONITORING OF IMATINIB IN GIST PATIENTS | Feasibility Study for TDM of imatinib that was measured by HPLC. | 2014 |
| Ziprasidone as adjunctive therapy in severe bipolar patients treated with clozapine | Aim of the study was to confirm the efficacy and tolerability of ziprasidone as adjunctive therapy in bipolar patients partially responding to clozapine or with persisting negative symptoms, overweight, or with metabolic syndrome. Clozapine and active metabolites were measured with an HPLC assay from Chromsystems | 2014 |
| Assessment of Hepatic Detoxification Activity: Proposal of an Improved Variant of the (13)c-methacetin Breath Test | Levetiracetam was measured by a Chromsystems HPLC assay in this clinical study. | 2013 |
| Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients With Hematological Malignancies | In conclusion, potential factors like younger age, prophylaxis, underlying hematological malignancy, BMI, and concomitant PPI should be considered within the algorithm of voriconazole treatment.Voriconazole plasma concentrations were measured with an HPLC assay. | 2013 |
| Poster: Therapeutic Drug Monitoring of Antiepileptic Drugs During Pregnancy | Clearance changes during pregnancy can lead to sub-therapeutic plasma levels of the AEDs. Pregnancy thus warrants a special case for the TDM of these medications As the numbers of these drugs seems to be ever increasing, a multiplexed assay strategy for their measurement seems appropriate. | 2013 |
| Population pharmacokinetics of lamotrigine in Chinese children with epilepsy | A PPK model of lamotrigine (LTG) in Chinese children with epilepsy was successfully established with NONMEM. LTG concentrations can be predicted accurately by this model. The model may be very useful for establishing initial LTG dosage guidelines. LTG was measured with Chromsystems HPLC assay. | 2012 |
| Augmentation of Clozapine With Aripiprazole in Severe Psychotic Bipolar and Schizoaffective Disorders: A Pilot Study | . A possible pharmacokinetic interaction between clozapine and aripiprazole does not account for the improved clinical benefit obtained after aripiprazole augmentation, according to the study that used a Chromsystems HPLC for the determination of clozapone and its metabolites. | 2010 |
| Title | Summary | Year |
| Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum | The paper describes a multi-analyte LC-MS/MS method for the quantification of repurposed COVID-19 drugs in human serum. It uses the column of Series A in combination with calibrators and controls for the COVID-19 drugs from Chromsystems. | 2021 |
| Interpretation of tandem mass spectra of antiepileptic drugs using accurate-m/z data and m/z-shifts with stable-isotope labeled analogues | This review helps in strengthening our understanding of the small-molecule fragmentation in MS–MS. In the case of AEDs, the structure proposals for the product ions can not only be confirmed with accurate-m/z data from high-resolution MS instruments, but also by studying m/z-shifts of products ions of the stable-isotope labeled analogues, that are frequently used as internal standard. | 2020 |
| Lack of concordance between EMIT assay and LC-MS/MS for Therapeutic Drug Monitoring of Mycophenolic Acid: Potential increased risk for graft rejection? | This study highlights a clinically relevant systematic overestimation of MPA concentration by EMIT, supporting the switch to LC–MS/MS techniques for TDM purpose. MPA was measured with the MassTOX Series A assay. | 2020 |
| Where clinical chemistry meets medicinal chemistry. Systematic analysis of physico-chemical properties predicts stability of common used drugs in gel separator serum tubes | For ease of handling and minimization of blood drawing times, the authors assume that tubes containing separator gel can be used for therapeutic drug monitoring of high hydrophilic drugs. In contrast lipophilic compounds showing logP higher than 3 and/or CF>20 should be critically considered and validated by extensive stability studies. Concentrations of selected drugs were measured with MassTox TDM Series A, AED parameter set. | 2019 |
| Poster: Inter- and intraindividual variations of methylphenidate in serum and oral fluid of ADHD patients | The LC-MS/MS kit MassTox TDM Parameter Set Antidepressants 2/Psychostimulants is suitable and reliable for the determination of methylphenidate and ritalinic acid in oral fluid. Measured serum concentration values for methylphenidate correspond to the previously published data. |
2016 |
| Poster: Methylphenidate and ritalinic acid determination in serum and saliva from patients with attention deficit hyperactivity disorder | The MassTox® TDM Parameter Set Antidepressants from Chromsystems is methodologically and analytically suitable for the determination of MPH and its main metabolite RA in serum/plasma as well as saliva by LC-MS/MS. This allows a substantially simplified form of drug monitoring in pediatric pharmacotherapy. Measured serum concentrations for methylphenidate correspond with the usual and published data | 2014 |
Please find here publications as guides for reference ranges or therapeutic ranges. They may differ from other published data and are only intended to serve as a rough guide. As data vary depending on patient population and measurement method, please determine ranges for your laboratory. When determining ranges make sure that you comply with local national requirements.